Korean J Intern Med.
2024 Mar;39(2):306-317. 10.3904/kjim.2023.303.
Relationship between metformin use and mortality in tuberculosis patients with diabetes: a nationwide cohort study
- Affiliations
-
- 1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- 2Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea
- 3Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
- 4Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
- 5Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea
- 6Jeju Double Cross Clinic, Korean National Tuberculosis Association, Jeju, Korea
- 7Department of Health Policy Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea
- 8Department of Preventive Medicine, Konyang University College of Medicine, Daejeon, Korea
- 9Institute of Immunology and Immunological Disease, Yonsei University College of Medicine, Seoul, Korea
- KMID: 2552949
- DOI: http://doi.org/10.3904/kjim.2023.303
Abstract
- Background/Aims
To determine whether metformin, which is considered a host-directed therapy for tuberculosis (TB), is effective in improving the prognosis of patients with TB and diabetes mellitus (DM), who have higher mortality than those without DM.
Methods
This cohort study included patients who were registered as having TB in the National Tuberculosis Surveillance System. The medical and death records of matched patients were obtained from the National Health Information Database and Statistics Korea, respectively, and data from 2011 to 2017 were collected retrospectively. We classified patients according to metformin use among participants who used diabetes drugs for more than 28 days. The primary outcome was all-cause mortality during TB treatment. Double propensity score adjustment was applied to reduce the effects of confounding and multivariable Cox proportional hazard models were used to estimate adjusted hazard ratio (aHR) with 95% confidence interval (CI).
Results
The all-cause mortality rate during TB treatment was lower (9.5% vs. 12.4%, p < 0.01) in the metformin user group. The hazard of death due to all causes after double propensity score adjustment was also lower in the metformin user group (aHR 0.76, 95% CI 0.67–0.86, p < 0.01). There was no significant difference in mortality between metformin users and non-users for TB-related deaths (p = 0.22); however, there was a significant difference in the non-TB-related deaths (p < 0.01).
Conclusions
Metformin use in patients with TB–DM co-prevalence is associated with reduced all-cause mortality, suggesting the potential for metformin adjuvant therapy in these patients.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Diabetes and Tuberculosis
- Effects of Metformin on Breast Cancer Risk and Mortality in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
- Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
- Recent Perspective of Metformin
- Metformin and Cancer in Type 2 Diabetes
